Battling cancer is the most related news in the century and breast cancer, alone, is one of the most common leading causes of death. Jim Dallke, Associate Editor of Chicago Inno stated that Tempus is the cancer-fighting startup that wants to give the physicians at the University of Chicago genomic sequencing data that will change how data will influence treatment success in the future. Data is important to use in medicine due to statistics, patterns and molecular spreadsheets.
Tempus`s founder Eric Lefkofsky started partnering with University of Chicago Medicine in 2015 and this year the project is taking off. This alliance is bound to provide data used to change treatment plans. The data sequencing will be used to monitor how patients respond to treatment plans. Genetic information isn`t sequenced enough so that physicians can improve treatment decisions, so the molecular data being processed will increase positive patient outcomes. Tempus steadily impacts the healthcare society and strives to accelerate private institutions order of science so that patients can go home to their families. Lefkosfy`s numerous community ventures started in Chicago, his hometown in which are initial startups called Groupon, Lightbank, and Drivin.
Who is Eric Lefkofsky?
Eric Lefkofsky graduated from the University of Michigan and is the CEO of Tempus and co-founder of several companies such as Groupon, Echo Global Logistics, InnerWorkings, Mediaocean and Uptake. He supports several ongoing charities by creating, buying and selling companies then giving a portion of that money back to the communities such as health, education, human rights, arts and culture. Lefkofsky`s confidence in business partnerships strengthens our outlook on the future of fighting cancer once and for all.
As he continues to change lives, accelerated disruption is proving to be one of his best idea for positive business outcomes for doctors, colleges, patient services and overall research science.